Key result
In the Colombian Heart Failure Registry, 88.9% of HFrEF patients were prescribed beta-blockers, 72.3% ACEI/ARBs, 67.9% MRAs, and 13.1% ARNIs, with less than a third reaching target doses.
Why the study?
Despite guideline recommendations for HFrEF medical therapy, gaps in medication prescription and dosage remain in Colombia.
Observational (n=1,384)
Yes
In a Colombian registry of HFrEF patients, prescription rates for beta-blockers and MRAs were high, but ARNI use and achievement of target doses for all guideline-directed medical therapies remained suboptimal.
Suboptimal GDMT prescription and dosing in Colombian HFrEF patients signals implementation gaps; leaves open generalizability beyond this registry.
INTRODUCTION: Although several guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF) be treated with angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs) or angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitor (SGLT2i), there are still several gaps in their prescription and dosage in Colombia. This study aimed to describe the use patterns of HFrEF treatments in the Colombian Heart Failure Registry (RECOLFACA). METHODS: Patients with HFrEF enrolled in RECOLFACA during 2017-2019 were included. Heart failure (HF) medication prescription and daily dose were assessed using absolute numbers and proportions. Therapeutic schemes of patients treated by internal medicine specialists were compared with those treated by cardiologists. RESULTS: Out of 2,528 patients in the registry, 1,384 (54.7%) had HFrEF. Among those individuals, 88.9% were prescribed beta-blockers, 72.3% with ACEI/ARBs, 67.9% with MRAs, and 13.1% with ARNIs. Moreover, less than a third of the total patients reached the target doses recommended by the European HF guidelines. No significant differences in the therapeutic schemes or target doses were observed between patients treated by internal medicine specialists or cardiologists. CONCLUSION: Prescription rates and target dose achievement are suboptimal in Colombia. Nevertheless, RECOLFACA had one of the highest prescription rates of beta-blockers and MRAs compared to some of the most recent HF registries. However, ARNIs remain underprescribed. Continuous registry updates can improve the identification of patients suitable for ARNI and SGLT2i therapy to promote their use in clinical practice.
No takes yet. Share an insight, caveat, or question.
Rivera-Toquica et al. (2024) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=1,384). Guideline-directed medical therapy (beta-blockers, ACEI/ARBs, MRAs, ARNIs) was evaluated on Prescription rates and daily doses of HFrEF medications. In the Colombian Heart Failure Registry, 88.9% of HFrEF patients were prescribed beta-blockers, 72.3% ACEI/ARBs, 67.9% MRAs, and 13.1% ARNIs, with less than a third reaching target doses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on HFrEF treatmentMore from Cardiology